Bezafibrate may attenuate biliary damage associated with chronic liver diseases accompanied by high serum biliary enzyme levels
Authors:
- 1 June 2006
- journal article
- clinical trial
- Published by Springer Nature in Journal of Gastroenterology
- Vol. 41 (7) , 686-692
Abstract
Bezafibrate is a commonly used medicine for hyperlipidemia, and recently several reports have suggested the efficacy of bezafibrate for the treatment of primary biliary cirrhosis (PBC). To assess its efficacy for other liver diseases, we administered bezafibrate to patients with various categories of hepatobiliary impairment. Bezafibrate (400 mg/day) was orally administered to 67 patients with chronic liver disease [22 with PBC, six with primary sclerosing cholangitis (PSC), 20 with chronic liver disease associated with hepatitis C virus (HCV) infection (CLD-C), seven with auto immune hepatitis (AIH), ten with alcoholic liver injury, and two with drug-induced liver injury]. The levels of biliary enzymes, such as alkaline phosphatase and γ-glutamyltranspeptidase, decreased promptly and dramatically. The abnormally high level of alanine aminotransferase also showed a gradual decrease over 6 months in five of the eight PBC patients, all three PSC patients, eight of the 17 CLD-C patients, and all seven alcoholic liver injury patients. The level of immunoglobulin M showed a gradual decrease in 17 of the 22 PBC patients. Bezafibrate significantly reduced the level of biliary enzymes in various chronic liver diseases and may be useful for the treatment of certain liver disease subsets.Keywords
This publication has 24 references indexed in Scilit:
- International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitisJournal of Hepatology, 1999
- Peroxisome Proliferator-activated Receptor α Negatively Regulates the Vascular Inflammatory Gene Response by Negative Cross-talk with Transcription Factors NF-κB and AP-1Journal of Biological Chemistry, 1999
- Bezafibrate may have a beneficial effect in pre-cirrhotic primary biliary cirrhosisHepatology Research, 1999
- Ursodiol for Primary Sclerosing CholangitisNew England Journal of Medicine, 1997
- Efficacy of ursodeoxycholic acid treatment and endoscopic dilation of major duct stenoses in primary sclerosing cholangitisJournal of Hepatology, 1997
- The PPARα–leukotriene B4 pathway to inflammation controlNature, 1996
- Homozygous disruption of the murine MDR2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver diseaseCell, 1993
- Effects of Bezafibrate?A Hypolipidemic DrugCardiovascular Drug Reviews, 1992
- Ursodeoxycholic acid for the treatment of primary biliary cirrhosisJournal of Hepatology, 1990
- Primary sclerosing cholangitis: Natural history, prognostic factors and survival analysisHepatology, 1989